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Abstract
Prostate cancer (CaP) is the most commonly diagnosed cancer in males in western countries. Orthotopic implantation is
considered as an ideal xenograft model for CaP study, and noninvasive measurement of tumor volume changes is important for
monitoring responses to anticancer therapies. In this study, the T2-weighted fast spin echo sequence magnetic resonance imaging
(MRI) was performed on a CaP orthotopic non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mouse model
weekly for 6 weeks post PC-3 CaP cell inoculation, and the fat signal was suppressed using a chemical shift-selective pulse.
Subsequently, the MRI data were imported into the image processing software Avizo Standard and stacked into three-dimensional
(3D) volumes. Our results demonstrate that MRI, combined with 3D reconstruction, is a feasible and sensitive method to assess
tumor growth in a PC-3 orthotopic CaP mouse model and this established monitoring approach is promising for longitudinal
observation of CaP xenograft development after anticancer therapy in vivo. Further investigation is needed to validate this
protocol in a larger cohort of mice to generate enough statistical power.
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Introduction
Prostate cancer (CaP) is the most commonly diagnosed cancer
and the second leading cause of cancer-related death in males
in the United States in 2017.1 To further facilitate the transla-
tion of scientific findings, reliable preclinical model systems
that accurately mimic the clinical scenarios are needed. Ortho-
topic implantation is considered as an ideal xenograft model for
more realistic modelling of the tumor microenvironment influ-
ence.2 One major challenge for many preclinical studies to
investigate CaP in preclinical models is the lack of reliable
approaches to monitor tumor growth in a longitudinal fashion.
Noninvasive prostatic tumor imaging constitutes a major step
forward in terms of assessment of tumor growth and evaluation
of the efficacy of cancer treatment.
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Specifically, magnetic resonance imaging (MRI) offers
reliable visualization of soft tissues and thus has shown
advantages as a means to better select patients for biopsy and
identify lesions for biopsy in the clinical setting for CaP diag-
nosis. It is also useful in tumor staging and treatment response
monitoring.
In preclinical CaP animal model imaging, MRI is thought to
be the superior choice due to its high resolution and superior
soft tissue contrast. Dedicated MRI pulse sequences allow for
the identification of different structures based on tissue char-
acteristics of the prostate gland or the tumor tissue.3 Ravoori
et al used T2-based Dixon “water only” sequence to clearly
visualize the mouse prostate gland in young and old mice4; it
was also reported by Mallett et al that MRI using the balanced
steady-state free precession sequence could identify prostate
tumors both anatomically and functionally.5 In order to clearly
detect extracapsular prostate tumor extension which is sur-
rounded by the periprostatic fat, fat suppression techniques
such as chemical shift-selective (CHESS) pulse have been
developed to repress the signal from the fat.6,7
Compared to human prostate, mouse prostate gland has a
larger anatomical variation and does not remain fixed, which
makes it challenging to be identified.8 Three-dimensional (3D)
volumetric MRI has been used in various oncologic applications
for tumor detection such as in central nervous and musculoske-
letal systems.9-11 The purpose of this study is to show the utility
of a novel 2-dimensional (2D)-T2w fast spin echo (FSE)
sequence combined with CHESS fat suppression to monitor
prostate tumor growth in an orthotopic non-obese diabetic/severe
combined immunodeficiency (NOD/SCID) mouse model and to
assess the feasibility and accuracy of tumor volume measure-
ment using 3D reconstruction from 2D slices. The results may
have significant implications in monitoring treatment effects of
CaP after different modalities in the preclinical study.
Materials and Methods
Cell Line and Cell Culture
The androgen-independent PC-3 CaP cell line was obtained
from American Type Culture Collection (Rockville, Maryland)
and cultured in Roswell Park Memorial Institute (RPMI)
1640 medium supplemented with 10% fetal bovine serum,
50 U/mL of penicillin, and 50 mg/mL of streptomycin, and
maintained in a humidified incubator at 37C and 5% CO2.
Subconfluent cells were harvested and centrifuged at 180 g
for 5 minutes, followed by resuspension in the Dulbecco’s
phosphate-buffered saline (DPBS) for animal study.
Animal Model
Three male, 6 weeks old NOD/SCID mice (Animal Resources
Centre, Western Australia, Australia) were housed under
specific pathogen-free conditions and all experiments were
performed in a laminar flow cabinet. Mice were kept at least
1 week before experimental manipulation. All mice were
monitored daily and the weights were recorded at least twice
a week.
Mice were anesthetized and placed in supine position. After
a lower midline laparotomy incision, 50 mL DPBS suspension
containing 1  106 PC-3 CaP cells were injected into the ven-
tral prostatic lobe, followed by muscle layer and skin clo-
sures.12 Starting from the first week after cell implantation,
tumor progression was monitored weekly by MRI.
Magnetic Resonance Imaging Protocol
All imaging was performed using a 9.4-T Bruker BioSpec
94/20 Avance III micro-imaging system (Bruker, Ettlingen,
Germany) equipped with BGA-12 S hyperpolarized (HP) gra-
dients with maximum strength 660 mT/m and slew rate 4570
Tm/s and a 35-mm quadrature radiofrequency coil. Prior to
imaging, animals were anesthetized in an induction chamber
with 4% isoflurane/oxygen mixture (1 L/min). Animals were
then transferred to the scanner animal bed and received 2% to
2.5% isoflurane at 0.8 L/min oxygen flow rate through a nose
cone to maintain anesthesia during the scanning procedure.
Respiratory motion was monitored during the imaging proce-
dures using a pressure sensitive pad. Animal body temperature
was maintained at 36C by a temperature controlled circulating
water warming blanket.
At each time point MR images were acquired in axial
orientation. To minimize susceptibility artefacts and signal
dephasing in the heterogenous abdominal region, we optimized
a 2D FSE (TurboRARE) sequence. In contrast to gradient echo
techniques which are commonly used in such studies,5 the spin-
echo-based method refocuses effects from static spin dephasing
while still maintaining high temporal efficiency by using an
echo train of refocusing pulses. The sequence was optimized for
best T2 contrast and low artefacts (from susceptibility and fat
shifts) specifically in the tissues inside and surrounding the
prostate tumor while still maintaining high signal-to-nosie ratio
(SNR) and good tumor delineation using the following general
imaging parameters: Echo Time (TE)¼ 21 milliseconds, Repe-
tition Time (TR) ¼ 2177 milliseconds, Bandwidth (BW) ¼
80000 Hz, Echo Train Length (ETL) ¼ 8, slice thickness ¼
500 mm, field of view 30  30 mm, matrix size 192  192,
in-plane resolution 156  156 mm, 30 slices, and total acquisi-
tion time 11 minutes. The relatively short echo time was able to
maintain good T2 contrast while reducing signal decay and sus-
ceptibility problems in our high field system in the heteroge-
neous pelvic region and therefore was able to maintain the most
favorable contrast-to-noise ratio (CNR) around the prostate.
To minimize abdominal fat signals, we have used relatively
high spectral BW as a compromise between signal and shift
distance. The fat signal was additionally suppressed using a
CHESS-based preparation scheme prior to the image readout.
The suppression used a Gaussian saturation pulse with pulse
duration of 1.957 milliseconds and BW of 1400 Hz. Signal was
subsequently spoiled using a 130 mT gradient pulse applied in
slice encoding direction for 2 milliseconds. Overall duration of
fat saturation preparation was 5.2 milliseconds.
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Three-Dimensional Reconstruction and Tumour
Volume Measurements
MR data from the weekly scanning was converted from Bru-
ker proprietary (2dseq) format into 30 DICOM (Digital Ima-
ging and Communications in Medicine) slices per animal and
time point. The MR data were then imported into the image
processing software Avizo Standard (version 8.1; FEI Visua-
lization Sciences Group, Hillsboro, Oregon) and stacked into
a 3D volume within the software. The MR images were
segmented by manually delineating the hyperintense prostate
area on each 2D slice and pixels inside the prostate were
assigned to a color-coded material mask. The volume of the
tumor was estimated by adding up the individual voxel
volumes inside the tumor while taking partial volume effects
on the boundaries of the surface into account using the Mate-
rial Statistics tool in Avizo Standard. From this the material
mask, a 3D surface model reconstruction of the tumor was
generated using the SurfaceGen tool in Avizo, enclosing all
the segmented voxels.
Tumor Growth Curve and Statistical Analysis
Tumor growth was investigated by calcualting tumor volumes
for each longtitudinal time point and then fitting an exponential
growth model by nonlinear regression using GraphPad Prism 7
package (GraphPad, California). Value of P < 0.05 is consid-
ered statistically significant. Upon sacrifice, primary prostate
tumors were harvested from the mice and measured by a cal-
liper. The gross tumor volumes were calculated as follows:
length  width  height  0.52 (in millimeters). Pearson cor-
relation coefficients were used to assess the degree of correla-
tion of two cohorts of data. Agreement of the MRI and gross
pathology volumetric measurements were assessed using
Bland-Altman analysis.
Results
T2w MRI Is a Useful tool to Monitor Prostate Tumor
Growth in the Orthotopic Mouse Model
In this study, the prostate gland and the tumor were easily
visualized in MR images. It was found the prostate gland was
discernible by its position and shape at the beginning, and was
engulfed within the tumor and became indistinguishable as
tumor grow at late stages.
In the images from early time points, the prostate gland was
found to be visible as a darker tissue whereas the tumor pre-
sents as a hyper-intense lesion (Figure 1). We found substantial
signal heterogeneities within the tumor. We attribute the hyper-
intense regions to regions with relative high water content,
possibly caused by edema, whereas dark regions are
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Figure 1. Representative MRI images of longitudinal tumor growth in the orthotopic mouse model. A-F, Images were acquired at 1,2,3,4,5, and
6 week(s) post CaP cell inoculation, respectively. A-D were acquired from mouse 1, and E, F were acquired from mouse 2. Prostate cancer
(CaP) tumorigenesis as early as 1 week after cell inoculation could be detected, and CaP tumor is clearly delineated from surrounding anatomies.
Blue line delineates the prostate gland; Yellow arrow indicates prostate tumor boundaries; red star indicates the urinary bladder. CaP, prostate
cancer; MRI, magnetic resonance imaging.
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presumably highly vascularized regions or necrotic regions
with components of hemorrhage. Compartmentation was also
noticed in the tumor region only at the late stages but not at
early stages (Figure 1E and F).
Longitudinal Imaging of Tumor Growth
Figure 1A-F shows the representative 2D images of 6 time
points (1-6 weeks post cell inoculation, respectively). The
tumor can be distinguished from the 2D-MRI image as early
as 1 week post cell injection. Image stacks were loaded into the
Avizo Standard software and reconstructed. Figure 2A-F
illustrates representative 3D rendering of the tumors from the
corresponding mouse in Figure 1, respectively.
Longitudinal tumor volume measurements were obtained
from all 3 mice and were plotted in Figure 3A. The results
indicate that the exponential growth functions fit the volume
data well (r2 ¼ 0.968, 0.966, 0.967, respectively).
Agreement of MRI and Gross Pathology Volume
Measurements
Paired volumetric measurements obtained from 3D reconstruc-
tion and the xenografts harvested at the end of the experiment
from 3 mice are plotted in Figure 3B. With linear regression,
Pearson correlation coefficient is r ¼ 0.92, but the P value is
0.25, indicating the correlation is not statistically significant.
The Bland-Altman scatter plot (Figure 3C) showed a
close agreement between MRI and xenograft measure-
ments. The difference was plotted against the average,
and the standard deviation of the difference (bias) was
6.25 mm3, which was quite small compared with the true
volume of the tumors.
Discussion
One of the major obstacles that is still hampering the wide-
spread use of CaP orthotopic xenograft models is the chal-
lenge of reliably imaging the orthotopic tumor growth and
metastasis. Ideally, a small-animal preclinical imaging tech-
nology should be sensitive to detect the tumors, acquire
high-quality images rapidly, easy to maintain, and harmless
to the animals.13
The most frequently-used technique to monitor tumor
growth in orthotopic xenograft models of CaP is biolumines-
cence imaging (BLI).14 Prostate cancer xenograft models were
among the first models demonstrating exciting BLI results.15,16
Bioluminescence imaging is fast, easy, and relatively inexpen-
sive but also comes along with severe drawbacks. Specifically,
the method is restricted to luciferase-transfected tumor cells,
which always requires genetic modification. BLI has inherently
very low spatial resolution, restricting it to 2D projection acqui-
sitions and the quantification of the tumor progression is very
difficult due to light scattering and poor spatial resolution.
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Figure 2. Representative 3D reconstructed MRI images of longitudinal tumor growth in the orthotopic mouse model. A-F, Using Avizo
Standard software, MRI scan slices acquired from the same mouse were reconstructed into 3D (outlined by blue surface) at 6 different time
points, respectively. 3D, three-dimensional; MRI, magnetic resonance imaging.
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Ultrasound is also widely used in the detection of tumor
growth in CaP orthotopic xenograft models but exhibits limited
image quality and exact definition of tumor volume remains
difficult. In a previous parallel study, our group has demon-
strated that 3D ultrasound is a useful, economical, and sensitive
method to monitor longitudinal tumor growth in the orthotopic
CaP mouse model,13 allowing for high spatial resolution and
contrast with fast and uncomplicated protocols. However,
ultrasound faces challenges due to small penetration depth,
ultrasonic scattering and susceptibility of acoustic impedance
barriers in tissues, limiting the visibility of specific structures.
MRI meets all criteria listed above and is a powerful and
useful imaging modality and has been used extensively for
detecting and modelling CaP in humans and preclinical appli-
cations,17,18 such as early detection of CaP, active surveillance
for low-risk patients, as well as targeted biopsies of the prostate
in clinical settings.19 Magnetic resonance imaging has also
been shown to be useful in the detection of preclinical CaP
mouse xenografts models. Previous studies have used both
gradient echo (GRE)-based and spin-echo-based MRI methods
to detect and delineate CaP. Using balanced steady-state free
precession sequences, Mallett et al showed that GRE-based
MRI can successfully monitor tumor growth in orthotopic
PC-3M tumors,5 and Li et al have studied visibility of CaP,
with the finding that visibility in these methods depends on
gene expression in the tumor.3 Previously, spin-echo-based
sequences have been used which (due to the refocusing of static
inhomogeneities) generally provide better stability in abdom-
inal regions but often come with the downside of long scan
times. Ravoori et al used T2-based Dixon water-only sequences
to depict the mouse prostate in young and old nude mice at 4.7
and 7 T.4 Song et al demonstrated that T2-diffusion-weighted
imaging (DWI) could detect tumors <1 mm in diameter and
distinguish benign and malignant prostatic tissue in a CR2-TAg
transgenic mouse model.20 Due to the single spin echo acquisi-
tions, such methods take a relatively long time; in this study,
we have adapted and optimized a T2w FSE sequence to mon-
itor the intraprostatic tumor growth in a PC-3 CaP mouse xeno-
graft model. The use of an FSE sequence circumvents the
sensitivity to the very abundant susceptibility variations in the
abdomen that GRE-based methods commonly face while still
maintaining high SNR and relatively short acquisition times.
Using relatively short TE in conjunction with fat suppression
allowed us to benefit from the high stability of spin echo meth-
ods in relatively quick scans of *10 minutes while maintain-
ing high stability. Our results indicate that MRI with T2w FSE
sequence is able to detect an intraprostatic tumor as early as 1
week post cell inoculation, and also showed a good agreement
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Figure 3. Exponential growth curves for longitudinal 3D volumetric measurements, correlation and agreement of 3D MRI with gross pathology
measurements. A, Three-dimensional MRI prostate tumor volumes from the 3 mice were plotted against time, with fitted exponential growth
curves, r2 ¼ 0.968, 0.966, and 0.967, respectively. B, Correlation of 3 paired tumor volumes measured by 3D MRI and gross pathology was
demonstrated by linear regression. Pearson r ¼ 0.92, P ¼ .24. C, Good agreement between 3D MRI and gross pathology measurements were
plotted and analyzed using Bland-Altman analysis. 3D, three-dimensional; MRI, magnetic resonance imaging; SD, standard deviation.
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between MRI measurement and gross pathology. One limita-
tion is that only 3 mice were tested in the study, which is not
enough for statistical power to reveal significant correlation.
Our imaging protocol also combined a CHESS pulse with
T2w FSE to eliminate the fat signal in the prostate region. To
obtain good fat suppression particularly when imaging abdom-
inal regions in high field scanners as ours, it is better to opti-
mize field homogeneity across the region of interest to enable
on resonance saturation of the fat protons in all regions. To
achieve this, we optimized main magnetic field homogeneity
in the tumor region using a field map–based shimming to the
second order prior to the actual image acquisition. This
approach was able to largely eliminate inhomogeneities and
optimize fat saturation in the tumor region. Due to susceptibil-
ity variations in the abdomen (eg, from air, tissue and water
boundaries in intestinum and bladder) which are specifically
strong in high field scanners as ours, some regions outside the
region of interest remained off-resonant to the CHESS pulse,
deteriorating fat saturation outside these regions, which didn’t
affect our analysis.
Additionally, MRI allows for the measurement of para-
meters other than volume: Mallett et al showed that hyperpo-
larized (HP) 13C magnetic resonance spectroscopic imaging
(MRSI) has the potential to assess tumor metabolism and
necrosis of orthotopic xenografts in a CaP nude mice model.5
Using the same technique, Aggarwal et al demonstrated that
HP 1-[13C]-pyruvate MRSI could detect the metabolic changes
within the prostate tumor as early as 6 weeks after the initiation
of androgen deprivation therapy, while there was no such a
response that could be ascertained using standard MRI.21
Taken together, we have successfully demonstrated that
MRI combined with 3D reconstruction is a feasible and sensi-
tive method to monitor tumor growth in a PC-3 orthotopic CaP
mouse model. Further investigation is needed to validate this
protocol in a larger cohort of mice to generate enough statisti-
cal power and to combine molecular imaging technologies to
supplement the current MRI protocols.
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